---
title: "Haemonetics Corporation Stock 12‑Month Price Target Raised to $98.9, Implies 10% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296204499.md"
description: "Haemonetics Corporation's average 12-month price target has been raised to $98.9 by 10 analysts, up from $96.9, implying a 10% upside based on the Aug. 17 closing price. Forecasts range from $86 to $120 per share. The consensus rating remains 'Buy' among 12 covering analysts, with 8 Buys and 4 Holds."
datetime: "2026-08-18T09:20:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296204499.md)
  - [en](https://longbridge.com/en/news/296204499.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296204499.md)
generator: "portal-rs"
---

# Haemonetics Corporation Stock 12‑Month Price Target Raised to $98.9, Implies 10% Upside

-   According to estimates from 10 analysts, Haemonetics Corporation stock's average price target has risen from $96.9 to $98.9, with forecasts ranging from $86 to $120 per share
-   Based on the Aug. 17 closing price, the updated target implies approximately 10% potential upside
-   Consensus rating remains at “Buy” across 12 covering analysts, with 8 Buys, 4 Holds and 0 Sells

Explore more price target data and ratings for Haemonetics Corporation on the , and track all previous and future analyst recommendations for Haemonetics Corporation in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [HAE.US](https://longbridge.com/en/quote/HAE.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Is Haemonetics’ (HAE) ESOP Shelf Move Reframing Its Balance Between Growth Investment and Shareholder Dilution?](https://longbridge.com/en/news/296298828.md)
- [Haemonetics: CSL Plasma Migration Deal Highlights Long-Term Upside but Near-Term Risk/Reward Keeps Rating at Hold](https://longbridge.com/en/news/296243457.md)
- [Does Interparfums’ (IPAR) Earnings Upgrade Hint At Deeper Strength In Its Profit Model?](https://longbridge.com/en/news/296564505.md)
- [This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday](https://longbridge.com/en/news/296352846.md)
- [CONMED (CNMD) Could Be 8% Overvalued Following Its Recent Rebound](https://longbridge.com/en/news/296318744.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**